Abstract:When a genetic disease is characterized by the abnormal activation of normal molecular pathways and cellular events, it is illuminating to critically examine the places and times of these activities both in health and disease. Therefore, because heterotopic ossification (HO) in fibrodysplasia ossificans progressiva (FOP) is by far the disease's most prominent symptom, attention is also directed toward the pathways and processes of bone formation during skeletal development. FOP is recognizable by effects of the causative mutation on skeletal development even before HO manifests, specifically in the malformation of the great toes. This signature skeletal phenotype is the most highly penetrant, but is only one among several skeletal abnormalities associated with FOP. Patients may present clinically with joint malformation and ankylosis, particularly in the cervical spine and costovertebral joints, as well as characteristic facial features and a litany of less common, non-skeletal symptoms, all stemming from missense mutations in the ACVR1 gene. In the same way that studying the genetic cause of HO advanced our understanding of HO initiation and progression, insight into the roles of ACVR1 signaling during tissue development, particularly in the musculoskeletal system, can be gained from examining altered skeletal development in individuals with FOP. This review will detail what is known about the molecular mechanisms of developmental phenotypes in FOP and the early role of ACVR1 in skeletal patterning and growth, as well as highlight how better understanding these processes may serve to advance patient care, assessments of patient outcomes, and the fields of bone and joint biology.

Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Modeling human somite development and fibrodysplasia ossificans progressiva with induced pluripotent stem cells

Creation of Induced Pluripotent Stem Cells RCMGi014-A Using Reprogramming of Urine Cells of a Patient with Fibrodysplasia Ossificans Progressiva Associated with Heterozygous Mutation in the ACVR1 Gene

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Generation of Fibrodysplasia Ossificans Progressiva and Control Integration Free Ipsc Lines from Periodontal Ligament Fibroblasts.

Current and emerging treatment modalities for fibrodysplasia ossificans progressiva

Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva

Patient-Derived Organoids Recapitulate Pathological Intrinsic and Phenotypic Features of Fibrous Dysplasia

Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells

Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia

Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva.

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva

Novel insights from human induced pluripotent stem cells on origins and roles of fibro/adipogenic progenitors as heterotopic ossification precursors

Molecular Developmental Biology of Fibrodysplasia Ossificans Progressiva: Measuring the Giant by Its Toe

Fibrodysplasia ossificans progressiva emerges from obscurity

Towards targeting overactive BMP signaling in Fibrodysplasia Ossificans Progressiva